Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 73-96

  Reilly, Timothy P ^a   Graziano, Michael J ^a   Janovitz, Evan B ^a   Dorr, Thomas E ^a   Fairchild, Craig ^a   Lee, Francis ^a   Chen, Jian ^a   Wong, Tai ^a   Whaley, Jean M ^a   Tirmenstein, Mark ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antidiabetic drug; Dapagliflozin; Experimental pharmacology; Glycemic control; SGLT2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

CYCLOPHOSPHAMIDE; DAPAGLIFLOZIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CARCINOGENICITY; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CYTOGENETICS; DNA REPAIR; DNA SYNTHESIS; DOG; FEMALE; GENE DELETION; GENETIC TRANSCRIPTION; GENOTOXICITY; GLUCOSURIA; HUMAN; HUMAN CELL; HYPERPLASIA; HYPOPHYSIS TUMOR; MALE; MAXIMUM PLASMA CONCENTRATION; MICRONUCLEUS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR PROMOTION; UROGENITAL TRACT TUMOR;

EID: 84898954869     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0053-3     Document Type: Article

References (55)

1. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+ /glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest. 1994;93:397–404.
2. Wallner EI, Wada J, Tramonti G, Lin S, Kanwar YS. Status of glucose transporters in the mammalian kidney and renal development. Ren Fail. 2001;23:301–10.
3. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723–9.
4. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51:1145–9.
5. +–glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48:1794–800.
6. Jabbour SA, Whaley JM, Tirmenstein M, et al. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med. 2012;124:62–73.
7. Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud. 2011;8:348–54.
8. Chen J, William S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1:57–92.
9. +–d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 2012;302:C1174–88.
10. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5:133–41.
11. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151–8.
12. Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: a meta-analysis. Endocr Relat Cancer. 2012;19:793–803.
13. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer. 2013;132:2186–91.
14. Tirmenstein M, Dorr TE, Janovitz EB, et al. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium–glucose contransporter 2 inhibitor. Int J Toxicol. 2013;32:336–50.
15. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium–glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38:405–14.
16. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium–glucose co-transporter type 2. Clin Pharmacokinet. 2014;53:17–27.
17. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–33.
18. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.
19. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–24.
20. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513–9.
21. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7.
22. Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–22.
23. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–8.
24. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–38.
25. Wilding JP, Norwood P, T’joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656–62.
26. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–15.
27. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510–6.
28. Ptaszynska A, Johnsson KM, Apanovitch AM, Sugg JE, Parikh SJ, List JF. Safety of dapagliflozin in clinical trials for T2DM [abstract]. Diabetes 2012;61(suppl 1):A258 (Abstract 1011-P).
29. Johnsson K, Ptaszynska A, Apanovitch AM, Sugg J, Parikh S, List J. Safety of dapagliflozin in clinical trials for T2DM. Presented at: European Association for the Study of Diabetes, Berlin; 2012 (Abstract 743).
30. US Food and Drug Administration. FDA briefing document for the July 19, 2011 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. NDA 202293; Dapagliflozin tablets. US Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf (Accessed January 9, 2014).
31. International Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). International Conference on Harmonisation Web site. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf (Accessed July 2, 2013).
32. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–12.
33. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011;33:1798–808.
34. Maeshima H, Ohno K, Tanaka-Azuma Y, Nakano S, Yamada T. Identification of tumor promotion marker genes for predicting tumor promoting potential of chemicals in BALB/c 3T3 cells. Toxicol In Vitro. 2009;23:148–57.
35. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203–23.
36. Gaillard ET. Ureter, urinary bladder, and urethra. In: Maronpot RR, Boorman GA, Gaul BW, editors. Pathology of the mouse—reference and atlas. Vienna: Cache River Press; 1999. p. 251–3.
37. Baylis C, Corman B. The aging kidney: insights from experimental studies. J Am Soc Nephrol. 1998;9:699–709.
38. Janssen Pharamecuticals I. FDA briefing document. NDA 204042. Invokana (canagliflozin) Tablets. FDA Web site. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (Accessed April 13, 2013).
39. Clayson DB, Cooper EH. Cancer of the urinary tract. Adv Cancer Res. 1970;13:271–381.
40. Mandell J, Koch WK, Nidess R, Preminger GM, McFarland E. Congenital polycystic kidney disease. Genetically transmitted infantile polycystic kidney disease in C57BL/6J mice. Am J Pathol. 1983;113:112–4.
41. Maeshima H, Ohno K, Nakano S, Yamada T. Validation of an in vitro screening test for predicting the tumor promoting potential of chemicals based on gene expression. Toxicol In Vitro. 2010;24:995–1001.
42. Dugdale DC. Glucose test-urine. MedlinePlus. http://www.nlm.nih.gov/medlineplus/ency/article/003581.htm (Accessed June 24, 2013).
43. Hard GC, Banton MI, Bretzlaff RS, et al. Consideration of rat chronic progressive nephropathy in regulatory evaluations for carcinogenicity. Toxicol Sci. 2013;132:268–75.
44. Osorio H, Bautista R, Rios A, et al. Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J Nephrol. 2010;23:541–6.
45. Sistare FD, Morton D, Alden C, et al. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol Pathol. 2011;39:716–44.
46. Everitt JI, Ross PW, Davis TW. Urologic syndrome associated with wire caging in AKR mice. Lab Anim Sci. 1988;38:609–11.
47. Maita K, Hirano M, Harada T, et al. Mortality, major cause of moribundity, and spontaneous tumors in CD-1 mice. Toxicol Pathol. 1988;16:340–9.
48. Son WC. Factors contributory to early death of young CD-1 mice in carcinogenicity studies. Toxicol Lett. 2003;145:88–98.
49. Hard GC, Khan KN. A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Toxicol Pathol. 2004;32:171–80.
50. Bucher JR, Huff J, Haseman JK, Eustis SL, Davis WE Jr, Meierhenry EF. Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. 2. Furosemide. J Appl Toxicol. 1990;10:369–78.
51. Tannock IF, Kopelyan I. Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res. 1986;46:3105–10.
52. Buckley LA, Sanbuissho A, Starling JJ, Knadler MP, Iversen PW, Jakubowski JA. Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent. Int J Toxicol. 2012;31:317–25.
53. Nelson JA, Falk RE. The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res. 1993;13:2287–92.
54. Nelson JA, Falk RE. Phloridzin and phloretin inhibition of 2-deoxy-d-glucose uptake by tumor cells in vitro and in vivo. Anticancer Res. 1993;13:2293–9.
55. Washburn WN. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat. 2009;19:1485–99.